These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34287280)

  • 21. Reimbursement recommendations for cancer drugs supported by phase II evidence in Canada.
    Li YYR; Mai H; Trudeau ME; Mittmann N; Chiasson K; Chan KKW; Cheung MC
    Curr Oncol; 2020 Oct; 27(5):e495-e500. PubMed ID: 33173389
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Are We Making a Difference? A Qualitative Study of Patient Engagement at the pan-Canadian Oncology Drug Review: Perspectives of Patient Groups.
    Mercer RE; Chambers A; Mai H; McDonald V; McMahon C; Chan KKW
    Value Health; 2020 Sep; 23(9):1157-1162. PubMed ID: 32940233
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
    Lemieux J; Audet S
    Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
    Rocchi A; Chabot I; Glennie J
    Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
    McDonald H; Charles C; Elit L; Gafni A
    J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Focused Jurisdictional Scan of Glomerulonephritis Medication Access in Canada: A Program Report.
    Naipaul R; Marques C; Ng J; Barbour S; Lo C; Hildebrand AM; Siu V; Prasad B; Laurin LP; Wazny LD; Armstrong S; Tran J; Sheffield M; Jauhal A; Hladunewich MA
    Can J Kidney Health Dis; 2023; 10():20543581231190227. PubMed ID: 37581108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
    Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
    J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pan-Canadian Pharmaceutical Alliance (pCPA): Timelines Analysis and Policy Implications.
    Salek SM; Lussier Hoskyn S; Johns J; Allen N; Sehgal C
    Front Pharmacol; 2018; 9():1578. PubMed ID: 30833899
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
    Niraula S
    Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of priority setting decisions for new cancer drugs on medical oncologists' practice in Ontario: a qualitative study.
    Berry SR; Hubay S; Soibelman H; Martin DK
    BMC Health Serv Res; 2007 Nov; 7():193. PubMed ID: 18042302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of rarity on Canadian oncology health technology assessment and funding.
    Keech J; Dai WF; Trudeau M; Mercer RE; Naipaul R; Wright FC; Ferguson SE; Darling G; Gavura S; Eisen A; Kouroukis CT; Beca J; Chan KKW
    Int J Technol Assess Health Care; 2020 Aug; ():1-6. PubMed ID: 32779560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Uncertainty tolerance among experts involved in drug reimbursement recommendations: Qualitative evidence from HTA committees in Canada and Poland.
    Wranik WD; Gambold L; Peacock S
    Health Policy; 2021 Mar; 125(3):307-319. PubMed ID: 33388158
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A scorecard for osteoporosis in Canada and seven Canadian provinces.
    Kendler DL; Adachi JD; Brown JP; Juby AG; Kovacs CS; Duperrouzel C; McTavish RK; Cameron C; Slatkovska L; Burke N
    Osteoporos Int; 2021 Jan; 32(1):123-132. PubMed ID: 32712739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
    Niraula S; Nugent Z
    J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
    [No Abstract]   [Full Text] [Related]  

  • 36. A Time-Trend Economic Analysis of Cancer Drug Trials.
    Cressman S; Browman GP; Hoch JS; Kovacic L; Peacock SJ
    Oncologist; 2015 Jul; 20(7):729-36. PubMed ID: 26032135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
    Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
    Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
    Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
    Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A deliberative framework to identify the need for real-life evidence building of new cancer drugs after interim funding decision.
    Leung L; de Lemos ML; Kovacic L
    J Oncol Pharm Pract; 2018 Dec; 24(8):584-598. PubMed ID: 28747103
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
    Yong JH; Beca J; Hoch JS
    Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.